185 related articles for article (PubMed ID: 38402346)
41. ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Reinhardt HC; Afanasyeva K; Avenoso D; Holderried TAW; Kornblit BT; Gavriilaki E; Martinez C; Chiusolo P; Mico MC; Dagunet E; Wichert S; Ozdogu H; Piekarska A; Kinsella F; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Bone Marrow Transplant; 2024 Mar; 59(3):380-386. PubMed ID: 38184740
[TBL] [Abstract][Full Text] [Related]
42. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
Escamilla Gómez V; García-Gutiérrez V; López Corral L; García Cadenas I; Pérez Martínez A; Márquez Malaver FJ; Caballero-Velázquez T; González Sierra PA; Viguria Alegría MC; Parra Salinas IM; Calderón Cabrera C; González Vicent M; Rodríguez Torres N; Parody Porras R; Ferra Coll C; Orti G; Valcárcel Ferreiras D; De la Cámara LLanzá R; Molés P; Velázquez-Kennedy K; João Mende M; Caballero Barrigón D; Pérez E; Martino Bofarull R; Saavedra Gerosa S; Sierra J; Poch M; Zudaire Ripa MT; Díaz Pérez MA; Molina Angulo B; Sánchez Ortega I; Sanz Caballer J; Montoro Gómez J; Espigado Tocino I; Pérez-Simón JA;
Bone Marrow Transplant; 2020 Mar; 55(3):641-648. PubMed ID: 31700138
[TBL] [Abstract][Full Text] [Related]
43. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
[TBL] [Abstract][Full Text] [Related]
44. Efficiency and Toxicity of Ruxolitinib as the Salvage Treatment in Steroid-Refractory Acute Graft-Versus-Host Disease after Haplo-Identical Stem Cell Transplantation.
Liu Y; Fan Y; Zhang W; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Transplant Cell Ther; 2021 Apr; 27(4):332.e1-332.e8. PubMed ID: 33836880
[TBL] [Abstract][Full Text] [Related]
45. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
Schroeder MA; Hari PN; Blithe A; Paranagama D; Bhatt V; DiPersio JF
Bone Marrow Transplant; 2022 Jun; 57(6):975-981. PubMed ID: 35437311
[TBL] [Abstract][Full Text] [Related]
46. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.
Spałek A; Wieczorkiewicz-Kabut A; Koclęga A; Woźniczka K; Węglarz P; Boral K; Kata D; Zielińska P; Helbig G
Int J Hematol; 2022 Dec; 116(6):922-928. PubMed ID: 35972605
[TBL] [Abstract][Full Text] [Related]
47. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
[TBL] [Abstract][Full Text] [Related]
48. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Belina ME; Driscoll TA; Blanchard SK; Cardones AR
Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
[TBL] [Abstract][Full Text] [Related]
49. Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes.
Herzog S; Weisdorf DJ; Shanley R; Rayes A; Holtan SG; Young JA; MacMillan ML; El Jurdi N
Blood Adv; 2023 Jul; 7(14):3644-3650. PubMed ID: 37036949
[TBL] [Abstract][Full Text] [Related]
50. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M; Perales MA; Schroeder MA; Ali H; Shah NN; Chen YB; Fazal S; Dawkins FW; Arbushites MC; Tian C; Connelly-Smith L; Howell MD; Khoury HJ
Blood; 2020 May; 135(20):1739-1749. PubMed ID: 32160294
[TBL] [Abstract][Full Text] [Related]
51. Ruxolitinib for the treatment of graft-versus-host disease.
Ali H; Salhotra A; Modi B; Nakamura R
Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
[No Abstract] [Full Text] [Related]
52. Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract.
Biavasco F; Ihorst G; Wäsch R; Wehr C; Bertz H; Finke J; Zeiser R
Bone Marrow Transplant; 2022 Oct; 57(10):1500-1506. PubMed ID: 35768570
[TBL] [Abstract][Full Text] [Related]
53. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
[TBL] [Abstract][Full Text] [Related]
54. Ruxolitinib for Therapy of Graft-versus-Host Disease.
Neumann T; Schneidewind L; Weigel M; Plis A; Vaizian R; Schmidt CA; Krüger W
Biomed Res Int; 2019; 2019():8163780. PubMed ID: 30956985
[TBL] [Abstract][Full Text] [Related]
55. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease.
Pusic I; Lee C; Veeraputhiran M; Minor C; DiPersio JF
Bone Marrow Transplant; 2024 Feb; 59(2):282-284. PubMed ID: 38071272
[No Abstract] [Full Text] [Related]
56. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.
Abedin S; Rashid N; Schroeder M; Romee R; Nauffal M; Alhaj Moustafa M; Kharfan-Dabaja MA; Palmer J; Hogan W; Hefazi M; Larson S; Holtan S; DeFilipp Z; Jayani R; Dholaria B; Pidala J; Khimani F; Grunwald MR; Butler C; Hamadani M
Br J Haematol; 2021 Nov; 195(3):429-432. PubMed ID: 34254289
[TBL] [Abstract][Full Text] [Related]
57. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
58. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
[TBL] [Abstract][Full Text] [Related]
59. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
Ren J; Lin K; Xu J; Lu Q; Luo Y; Lin C; Lu J; Weng Y; Zhang Y; Chen Z; Gale RP; Hu J; Yang T
Clin Transplant; 2024 Jan; 38(1):e15195. PubMed ID: 37987525
[TBL] [Abstract][Full Text] [Related]
60. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Le RQ; Wang X; Zhang H; Li H; Przepiorka D; Vallejo J; Leong R; Ma L; Goldberg KB; Pazdur R; Theoret MR; De Claro A
Oncologist; 2022 Jun; 27(6):493-500. PubMed ID: 35363318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
